SCHEMBL5239013

SCHEMBL5239013

COc1cc(OCc2ccccc2)c(C=O)c2oc3c(OCc4ccccc4)cccc3c(=O)c12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.47
MAOA P21397 8/20 0.45
CYP1A1 P04798 2/20 0.43
CYP1A2 P05177 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP1B1 Q16678 1/20 0.41
PPARG P37231 1/20 0.41
ERN1 O75460 1/20 0.41
ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281277 0.83 LOXL2 (0.44) LOXL2MAOACYP1A1CYP1A2NPC1
SCHEMBL5346660 0.75 MAOA (0.72) MAOACYP1A1CYP1A2NPC1RAB9A
SCHEMBL5239017 0.73 NPC1 (0.45) LOXL2MAOANPC1RAB9AMAPT
SCHEMBL751846 0.73 MAPT (0.57) NPC1RAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL2650035 0.72 MAPT (0.49) CYP1A1CYP1A2NPC1RAB9AMAPT
SCHEMBL11389530 0.72 MAOA (0.72) LOXL2MAOACYP1A2NPC1RAB9A
SCHEMBL5349187 0.72 MAOA (0.76) MAOANPC1RAB9AMAPTKDM4E
SCHEMBL18702691 0.70 MAPT (0.53) LOXL2MAOANPC1RAB9AMAPT
SCHEMBL29502965 0.70 MAPT (0.53) LOXL2MAOANPC1RAB9AMAPT
SCHEMBL28503954 0.70 PDE4A (0.48) NPC1RAB9AMAPTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585740-A4 PROCESS TO PREPARE PSOROSPERMIN CYLENE PHARMACEUTICALS INC (US) 2007-06-13 EP disclosed
EP-1585740-A2 PROCESS TO PREPARE PSOROSPERMIN Cylene Pharmaceuticals, Inc. (US) 2005-10-19 EP disclosed
US-6933396-B2 Process to prepare psorospermin CYLENE PHARMACEUTICALS (US) 2005-08-23 US disclosed
US-20040102515-A1 Process to prepare psorospermin CYLENE PHARMACEUTICALS 2004-05-27 US disclosed
WO-2004019888-A2 PROCESS TO PREPARE PSOROSPERMIN CYLENE PHARMACEUTICALS, INC. (US) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102515-A1 Process to prepare psorospermin BPGM, DHPS, FDPS LOXL2 3973/4885MAOA 761/4885CYP1A1 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.